In 2000, FDA approved Levaquin (levofloxacin) to treat penicillin-resistant S. pneumoniae in patients with community acquired pneumonia (CAP). Levaquin became the 1st antimicrobial medicine aimed to treat CAP caused by this microorganism. Now, in case of a present or suspected pneumonia resistant to penicillin, doctors are able to choose the best option for their patients. Levaquin 750 mg is the only medicine approved for a short-term (5 days) treatment of CAP. Read more...